Literature DB >> 1712553

Interleukin-1 and tumor necrosis factor-alpha inhibit erythropoietin production in vitro.

J Fandrey1, W E Jelkmann.   

Abstract

The effects of several immunomodulatory peptides (recombinant, human) on the in vitro production of erythropoietin (Epo) were studied in cultures of the human hepatoma cell line Hep G2. A dose-dependent decrease of up to 60% in Epo production was induced by interleukin-1 beta, interleukin-1 alpha, and tumor necrosis factor-alpha (in that order of potency). In contrast, moderately increased Epo levels resulted with interleukin-6 or interferon-gamma treatment at high concentrations. Concomitant measurements of the production of alpha-fetoprotein indicated that the observed effects were specific for Epo. Hence, we suspect a modulating role of the immune system in the in vivo control of Epo production and postulate that interleukin-1 and tumor necrosis factor-alpha are involved in some of the cases of lowered blood Epo levels in association with renal diseases, chronic inflammation, and malignancies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712553     DOI: 10.1111/j.1749-6632.1991.tb17252.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Serum cytokine profiles in patients with prostate carcinoma.

Authors:  Eri Tazaki; Nobuaki Shimizu; Ryota Tanaka; Masakazu Yoshizumi; Hiroshi Kamma; Shigeru Imoto; Tomoyuki Goya; Kunihisa Kozawa; Atsuyoshi Nishina; Hirokazu Kimura
Journal:  Exp Ther Med       Date:  2011-06-16       Impact factor: 2.447

2.  Timing and determinants of erythropoietin deficiency in chronic kidney disease.

Authors:  Lucile Mercadal; Marie Metzger; Nicole Casadevall; Jean Philippe Haymann; Alexandre Karras; Jean-Jacques Boffa; Martin Flamant; François Vrtovsnik; Bénédicte Stengel; Marc Froissart
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-17       Impact factor: 8.237

3.  Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

Authors:  Agata Poniewierska-Baran; Justyna Rajewska-Majchrzak; Mariusz Z Ratajczak
Journal:  J Cancer Stem Cell Res       Date:  2017-04-27

Review 4.  Acquired Aplastic Anemia as a Clonal Disorder of Hematopoietic Stem Cells.

Authors:  Katarzyna Brzeźniakiewicz-Janus; Joanna Rupa-Matysek; Lidia Gil
Journal:  Stem Cell Rev Rep       Date:  2020-06       Impact factor: 5.739

Review 5.  Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents.

Authors:  Jose Portolés; Leyre Martín; José Jesús Broseta; Aleix Cases
Journal:  Front Med (Lausanne)       Date:  2021-03-26

6.  Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis.

Authors:  Pia Villa; Paolo Bigini; Tiziana Mennini; Davide Agnello; Teresa Laragione; Alfredo Cagnotto; Barbara Viviani; Marina Marinovich; Anthony Cerami; Thomas R Coleman; Michael Brines; Pietro Ghezzi
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

Review 7.  The Effects of Altitude Training on Erythropoietic Response and Hematological Variables in Adult Athletes: A Narrative Review.

Authors:  Kamila Płoszczyca; Józef Langfort; Miłosz Czuba
Journal:  Front Physiol       Date:  2018-04-11       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.